Journal of Clinical Oncology, Vol 26, No 2 (January 10), 2008: pp. 183-189
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.13.8099
Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107
Axel Grothey,
Eric E. Hedrick,
Robert D. Mass,
Somnath Sarkar,
Sam Suzuki,
Ramesh K. Ramanathan,
Herbert I. Hurwitz,
Richard M. Goldberg,
Daniel J. Sargent
From the Mayo Clinic, Rochester, MN; Genentech Inc, South San Francisco, CA; Translational Genomics Research Institute, Scottsdale, AZ; Duke University, Durham, NC; and University of North Carolina, Chapel Hill, NC
Corresponding author: Axel Grothey, MD, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905; e-mail: grothey.axel{at}mayo.edu
Purpose In the phase III study AVF2107g, bevacizumab (BV) demonstrated a survival benefit when added to irinotecan, fluorouracil, and leucovorin (IFL) in first-line metastatic colorectal cancer (mCRC). In a parallel phase III study, Intergroup N9741, oxaliplatin plus fluorouracil and leucovorin (FOLFOX) also demonstrated a survival benefit compared with IFL. As these two superior therapies have differing mechanisms of action, we explored whether the improved survival associated with the superior therapy was dependent on tumor response.
Patients and Methods For these retrospective, exploratory analyses, patients were defined as responders or nonresponders by whether complete or partial response was achieved with first-line therapy.
Results Compared with IFL alone, BV plus IFL and FOLFOX each demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) regardless of objective tumor response. BV-treated nonresponders had a hazard ratio (HR) of 0.63 (P = .0001) for PFS and 0.76 (P = .0188) for OS compared with IFL-treated nonresponders. FOLFOX-treated nonresponders had an HR of 0.75 (P = .0029) for PFS and 0.74 (P = .0030) for OS compared with IFL-treated nonresponders.
Conclusion In both AVF2107g and N9741, objective response did not predict the magnitude of PFS or OS benefit from the superior therapy; nonresponders, despite a poorer prognosis than responders, achieved extended PFS and OS from BV plus IFL or FOLFOX compared with IFL. On the basis of these data, tumor response in metastatic colorectal cancer is not a necessary factor for a therapy to provide benefit to an individual patient.
Supported by National Cancer Institute Grant No. CA25224, by Sanofi Synthelabo (now Sanofi-Aventis), and by Pharmacia (now Pfizer).
Presented in part at the 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, Orlando, FL, and at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, Atlanta, GA.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. D. Saad, A. Katz, P. M. Hoff, and M. Buyse
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
Ann. Onc.,
November 9, 2009;
(2009)
mdp523v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Goldberg, D. J. Sargent, R. F. Morton, E. Green, H. K. Sanoff, H. McLeod, and J. Buckner
NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial
Oncologist,
October 1, 2009;
14(10):
970 - 978.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Piessevaux, M. Buyse, W. De Roock, H. Prenen, M. Schlichting, E. Van Cutsem, and S. Tejpar
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
Ann. Onc.,
August 1, 2009;
20(8):
1375 - 1382.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Rubinstein, J. Crowley, P. Ivy, M. LeBlanc, and D. Sargent
Randomized Phase II Designs
Clin. Cancer Res.,
March 15, 2009;
15(6):
1883 - 1890.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Dhani, D. Tu, D. J. Sargent, L. Seymour, and M. J. Moore
Alternate Endpoints for Screening Phase II Studies
Clin. Cancer Res.,
March 15, 2009;
15(6):
1873 - 1882.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. H. O'Neil and R. M. Goldberg
In Reply
Oncologist,
February 1, 2009;
14(2):
194 - 196.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Jubb
Biomarkers and Response to Therapy in Breast Cancer
Clin. Cancer Res.,
January 1, 2009;
15(1):
414 - 414.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-T. Arkenau, D. Arnold, J. Cassidy, E. Diaz-Rubio, J.-Y. Douillard, H. Hochster, A. Martoni, A. Grothey, A. Hinke, W. Schmiegel, et al.
Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials
J. Clin. Oncol.,
December 20, 2008;
26(36):
5910 - 5917.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. G. Blazer III, Y. Kishi, D. M. Maru, S. Kopetz, Y. S. Chun, M. J. Overman, D. Fogelman, C. Eng, D. Z. Chang, H. Wang, et al.
Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases
J. Clin. Oncol.,
November 20, 2008;
26(33):
5344 - 5351.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Shitara, M. Munakata, O. Muto, and Y. Sakata
Metastatic Rectal Cancer Responding to Third-line Therapy Employing Bevacizumab After Failure of Oxaliplatin and Irinotecan: Case Report
Jpn. J. Clin. Oncol.,
July 1, 2008;
38(7):
493 - 496.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|